FDAapproval95% confidence
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Supporting Context
- Therapeutic area
- Infectious Disease · HIV-1
- Sub-indication
- General
Related signal: Merck Receives FDA Approval for IDVYNSO, Expands Oncology Pipeline and Animal Health Sales